FDA declares Wegovy and Ozempic shortage over, Novo Nordisk confirms

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The FDA’s assessment confirms the U.S. supply of these prescription-only GLP-1 medicines now meets or exceeds both current and projected U.S. demand. We continue to operate production facilities 24 hours a day, seven days a week with all doses of Wegovy and Ozempic being shipped regularly to wholesalers. This update comes after ongoing dialogue with the FDA, and substantial efforts by Novo Nordisk to increase manufacturing capacity, including $6.5 billion dollars of investments in the U.S. this year alone,” the company stated.